Skip to main content

Table 2 Antimicrobial activity of omadacycline against Gram-negative bacilli organisms

From: Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study

Organism/organism group (number of isolates)

Number (cumulative %) of isolates at MIC (mg/L) of:

MIC50

MIC90

%S

%R

≤0.06

0.12

0.25

0.5

1

2

4

8

16

32

Enterobacterales (651)

1 (0.2)

0 (0.2)

11 (1.8)

86 (15.1)

182 (43.0)

151 (66.2)

101 (81.7)

63 (91.4)

31 (96.2)

25 (100.0)

2

8

  

  Ceftazidime-non-susceptible (275)

1 (0.4)

0 (0.4)

5 (2.2)

30 (13.1)

64 (36.4)

59 (57.8)

51 (76.4)

31 (87.6)

15 (93.1)

19 (100.0)

2

16

  

  Tetracycline-resistant (401)

 

0 (0.0)

1 (0.2)

40 (10.2)

108 (37.2)

76 (56.1)

66 (72.6)

54 (86.0)

31 (93.8)

25 (100.0)

2

16

  

  Tigecycline-non-susceptible (55)

     

0 (0.0)

2 (3.6)

12 (25.5)

18 (58.2)

23 (100.0)

16

32

  

Escherichia coli (260)

 

0 (0.0)

8 (3.1)

60 (26.2)

107 (67.3)

52 (87.3)

13 (92.3)

8 (95.4)

0 (95.4)

12 (100.0)

1

4

  

  Carbapenemase-producing (19)

  

0 (0.0)

6 (31.6)

6 (63.2)

4 (84.2)

3 (100.0)

   

1

4

  

  ESBL phenotype positive (134) a

 

0 (0.0)

6 (4.5)

28 (25.4)

57 (67.9)

16 (79.9)

9 (86.6)

6 (91.0)

0 (91.0)

12 (100.0)

1

8

  

  ESBL phenotype negative (107) a

 

0 (0.0)

2 (1.9)

26 (26.2)

44 (67.3)

32 (97.2)

1 (98.1)

2 (100.0)

  

1

2

  

  Tetracycline-resistant (221)

 

0 (0.0)

1 (0.5)

36 (16.7)

99 (61.5)

52 (85.1)

13 (91.0)

8 (94.6)

0 (94.6)

12 (100.0)

1

4

  

  Tigecycline-non-susceptible (1)

        

0 (0.0)

1 (100.0)

    

Klebsiella pneumoniae (271)

 

0 (0.0)

2 (0.7)

21 (8.5)

54 (28.4)

62 (51.3)

52 (70.5)

44 (86.7)

25 (95.9)

11 (100.0)

2

16

70.5 b,c

13.3 b,c

  Carbapenemase-producing (47)

  

0 (0.0)

3 (6.4)

0 (6.4)

13 (34.0)

18 (72.3)

6 (85.1)

5 (95.7)

2 (100.0)

4

16

72.3 b,c

14.9 b,c

  ESBL phenotype positive (118) a

  

0 (0.0)

4 (3.4)

14 (15.3)

25 (36.4)

25 (57.6)

28 (81.4)

13 (92.4)

9 (100.0)

4

16

57.6 b,c

18.6 b,c

  ESBL phenotype negative (106) a

 

0 (0.0)

2 (1.9)

14 (15.1)

40 (52.8)

24 (75.5)

9 (84.0)

10 (93.4)

7 (100.0)

 

1

8

84.0 b,c

6.6 b,c

  Tetracycline-resistant (127)

  

0 (0.0)

2 (1.6)

4 (4.7)

16 (17.3)

31 (41.7)

38 (71.7)

25 (91.3)

11 (100.0)

8

16

41.7 b,c

28.3 b,c

  Tigecycline-non-susceptible (6)

       

0 (0.0)

2 (33.3)

4 (100.0)

32

 

0.0 b,c

100.0b,c

Klebsiella aerogenes (30)

   

0 (0.0)

6 (20.0)

13 (63.3)

4 (76.7)

5 (93.3)

2 (100.0)

 

2

8

  

Enterobacter cloacae (30)

   

0 (0.0)

3 (10.0)

16 (63.3)

9 (93.3)

0 (93.3)

0 (93.3)

2 (100.0)

2

4

93.3b

6.7 b

  Ceftazidime-non-susceptible (16)

   

0 (0.0)

1 (6.2)

10 (68.8)

4 (93.8)

0 (93.8)

0 (93.8)

1 (100.0)

2

4

93.8b

6.2 b

  Tetracycline-resistant (11)

   

0 (0.0)

1 (9.1)

3 (36.4)

5 (81.8)

0 (81.8)

0 (81.8)

2 (100.0)

4

32

81.8b

18.2b

Citrobacter spp. (30)

1 (3.3)

0 (3.3)

1 (6.7)

5 (23.3)

12 (63.3)

5 (80.0)

2 (86.7)

2 (93.3)

2 (100.0)

 

1

8

  

  Tetracycline-resistant (11)

  

0 (0.0)

2 (18.2)

3 (45.5)

3 (72.7)

1 (81.8)

0 (81.8)

2 (100.0)

 

2

16

  

Serratia marcescens (30)

    

0 (0.0)

3 (10.0)

21 (80.0)

4 (93.3)

2 (100.0)

 

4

8

  

Acinetobacter baumannii (198)

8 (4.0)

14 (11.1)

15 (18.7)

7 (22.2)

16 (30.3)

38 (49.5)

52 (75.8)

24 (87.9)

18 (97.0)

6 (100.0)

4

16

  

Pseudomonas aeruginosa (30)

    

0 (0.0)

1 (3.3)

0 (3.3)

8 (30.0)

0 (30.0)

21 (100.0)

32

32

  

Stenotrophomonas maltophilia (30)

   

0 (0.0)

4 (13.3)

12 (53.3)

11 (90.0)

3 (100.0)

  

2

4

  

Moraxella catarrhalis (31)

1 (3.2)

25 (83.9)

5 (100.0)

       

0.12

0.25

  
  1. a ESBL: extended-spectrum β-lactamase
  2. b Using FDA identified breakpoints for ABSSSIs
  3. c Using FDA identified breakpoints for CABP
Back to article page

BMC Microbiology

ISSN: 1471-2180

Contact us